Table 1. Baseline demographic and clinical presentation of tuberculosis patients.
| Characteristics | Tuberculosis treatment | p-value | |
|---|---|---|---|
| RHZ1 (n = 365) |
RHEZ-FDC2 (n = 365) |
||
| Male sex | 208 (57.0) | 200 (54.8) | 0.68 |
| Age in years | 40.0 ± 13 | 36 ± 13 | <0.01 |
| Pulmonary tuberculosis presentation3 | 336 (92.1) | 324 (88.8) | 0.24 |
| Diabetes disease at diagnosis | 29 (4.9) | 33 (9.1) | 0.68 |
| Other comorbidities at diagnosis4 | 28 (7.7) | 36 (9.9) | 0.30 |
| Concomitant medication5 | 5 (1.4) | 9 (2.5) | 0.28 |
| Past or current cigarette smoking6 | 77 (21.1) | 99 (27.1) | 0.06 |
| Past or current alcohol consumption7 | 50 (13.7) | 67 (18.4) | 0.09 |
| MDR8 | 16 (4.4) | 18 (4.9) | 0.86 |
| Patients with ADRs9 | 55 (15.1) | 86 (23.6) | 0.01 |
Data represent no. (%). except age, represented in mean and standard deviation (SD)
1RHZ: Rifampicin (600mg), Isoniazid (400mg) and Pyrazinamide (2000mg). Dose to patients >45kg
2RHEZ: Rifampicin (150mg), Isoniazid (75mg), Ethambutol (275mg) and Pyrazinamide (400mg) (fixed dose combination-FDC). Dose to patients >50kg: 4 FDC.
3Pulmonary plus extra-pulmonary versus extra-pulmonary.
4Other comorbidities at diagnosis: stomach cancer, heart disease, mental disturbance, hypertension, bipolar disorder, psychotic outbreak, schizophrenia, rheumatoid arthritis, lymphedema, asthma, pyogenesis, pleural fibrosis, illicit drug use.
5Concomitant medication: Medicine taken concurrently with treatment anti-tuberculosis.
6Past or current cigarette smoker (daily use) versus no or sporadic use (non-smokers).
7Past or current alcohol consumption: regular (more than 3 days per week) versus no or sporadic–less than 3 days/week (non-drinkers).
8MDR: Multidrug resistance
9ADR: Adverse drug reactions